Gracell Biotechnologies Inc (DELISTED) (GRCL:DL)
10.25
0.00 (0.00%)
USD |
NASDAQ |
Feb 22, 16:00
Price Chart
Key Stats
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR. |
| URL | https://www.gracellbio.com |
| Investor Relations URL | https://ir.gracellbio.com/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | N/A |
| Next Earnings Release | Mar. 13, 2024 (est.) |
| Last Earnings Release | Nov. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR. |
| URL | https://www.gracellbio.com |
| Investor Relations URL | https://ir.gracellbio.com/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | N/A |
| Next Earnings Release | Mar. 13, 2024 (est.) |
| Last Earnings Release | Nov. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |